ArticleLung cancer (Amsterdam, Netherlands)2014
NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism.
Article in Lung cancer (Amsterdam, Netherlands), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Prognostic significance of NF-κB expression in non-small cell lung cancer: A meta-analysis.PloS one · 2018Pooled it
- NF-κB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis.Medicine · 2015Pooled it
- Co-treatment of Colchicine and Rosiglitazone synergistically inhibits cytokine-driven inflammation and modulates the related hsa-miRNA26a-5p, hsa-miRNA21-5p, and STAT3 expression in non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Radiogenomic landscape of the hallmarks of cancer.Biomarker research · 2026Review
- From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Prediction of the differences in tumor mutation burden between primary and metastatic lesions by radiogenomics.Cancer science · 2022Article
- A highly expressed mRNA signature for predicting survival in patients with stage I/II non-small-cell lung cancer after operation.Scientific reports · 2021Article
- Targeting NF-κB mediated cell signaling pathway and inflammatory mediators by 1,2-diazole in A549 cellsBiotechnology reports (Amsterdam, Netherlands) · 2021Article
- A multi-scale integrated analysis identifies KRT8 as a pan-cancer early biomarker.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2021Article
- Artificial intelligence and hybrid imaging: the best match for personalized medicine in oncology.European journal of hybrid imaging · 2020Review
- A Role for FDG PET Radiomics in Personalized Medicine?Seminars in nuclear medicine · 2020Review
- Article
- The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology.Frontiers in oncology · 2020Review
- IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function.Cell cycle (Georgetown, Tex.) · 2019Article
- What can artificial intelligence teach us about the molecular mechanisms underlying disease?European journal of nuclear medicine and molecular imaging · 2019Review
- Association of metabolic and genetic heterogeneity in head and neck squamous cell carcinoma with prognostic implications: integration of FDG PET and genomic analysis.EJNMMI research · 2019Article
- Diffusion-weighted MRI andEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer.European journal of nuclear medicine and molecular imaging · 2019Article
- Radiomic signature: a non-invasive biomarker for discriminating invasive and non-invasive cases of lung adenocarcinoma.Cancer management and research · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionWe previously demonstrated that NF-κB may be associated with (18)F-FDG PET uptake and patient prognosis using radiogenomics in patients with non-small cell lung cancer (NSCLC). To validate these results, we assessed NF-κB protein expression in an extended cohort of NSCLC patients.
methodsWe examined NF-κBp65 by immunohistochemistry (IHC) using a Tissue Microarray. Staining intensity was assessed by qualitative ordinal scoring and compared to tumor FDG uptake (SUVmax and SUVmean), lactate dehydrogenase A (LDHA) expression (as a positive control) and outcome using ANOVA, Kaplan Meier (KM), and Cox-proportional hazards (CPH) analysis.
results365 tumors from 355 patients with long-term follow-up were analyzed. The average age for patients was 67±11 years, 46% were male and 67% were ever smokers. Stage I and II patients comprised 83% of the cohort and the majority had adenocarcinoma (73%). From 88 FDG PET scans available, average SUVmax and SUVmean were 8.3±6.6, and 3.7±2.4 respectively. Increasing NF-κBp65 expression, but not LDHA expression, was associated with higher SUVmax and SUVmean (p=0.03 and 0.02 respectively). Both NF-κBp65 and positive FDG uptake were significantly associated with more advanced stage, tumor histology and invasion. Higher NF-κBp65 expression was associated with death by KM analysis (p=0.06) while LDHA was strongly associated with recurrence (p=0.04). Increased levels of combined NF-κBp65 and LDHA expression were synergistic and associated with both recurrence (p=0.04) and death (p=0.03).
conclusionsNF-κB IHC was a modest biomarker of prognosis that associated with tumor glucose metabolism on FDG PET when compared to existing molecular correlates like LDHA, which was synergistic with NF-κB for outcome. These findings recapitulate radiogenomics profiles previously reported by our group and provide a methodology for studying tumor biology using computational approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.